CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Cellinfinity Bio
Company Type: Therapeutics
Main focus: Gene-edited immune cells, e.g., natural killer cells and T cells.
Company stage: Pre-clinical
Diseases: multiple malignancies, including solid tumours
Genome-editing tool: CRISPR/Cpf1
Funding stage: Seeding
Location: West Haven, CT, USA
Website: https://www.cellinfinitybio.com
Pipeline: https://www.cellinfinitybio.com
Partners:
Cellinfinity Bio is a pre-clinical company focused on CRISPR-based engineering of immune cells, such as T cells and natural killer (NK) cells, to generate chimeric antigen receptors (CARs) targeted against multiple malignancies including solid tumours. By leveraging proprietary methods for directed evolution of cells, Cellinfinity identifies genetic modifications and CAR constructs that substantially improve engineered T-cell and NK-cell activities against solid tumours. Cellinfinity develops both first-in-class and best-in-class cell therapy products with the goal to benefit diverse patient populations with unmet medical needs.
